Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy

被引：0

作者：

Yoshiaki Nakamura

Takeharu Yamanaka

Keisho Chin

Haruhiko Cho

Hitoshi Katai

Masanori Terashima

Kazunari Misawa

Motohiro Hirao

Kazuhiro Yoshida

Eiji Oki

Mitsuru Sasako

Yasunori Emi

Hideaki Bando

Yoshiyuki Kawashima

Tetsu Fukunaga

Masahiro Gotoh

Takako Ishibashi

Kohei Shitara

机构：

[1] National Cancer Center Hospital East,Department of Gastroenterology and Gastrointestinal Oncology

[2] Yokohama City University,Department of Biostatistics

[3] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Gastroenterology

[4] Kanagawa Cancer Center,Department of Gastrointestinal Surgery

[5] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Surgery

[6] National Cancer Center Hospital,Division of Gastric Surgery

[7] Shizuoka Cancer Center,Division of Gastric Surgery

[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery

[9] National Hospital Organization Osaka National Hospital,Department of Surgery

[10] Gifu University,Department of Surgical Oncology, Graduate School of Medicine

[11] Kyushu University Hospital,Department of Surgery and Science, Graduate School of Medical Sciences

[12] Hyogo College of Medicine,Department of Surgery

[13] Saiseikai Fukuoka General Hospital,Department of Surgery

[14] Saitama Cancer Center,Department of Gastroenterological Surgery

[15] St. Marianna University School of Medicine,Department of Gastroenterological and General Surgery

[16] Osaka Medical College,Cancer Chemotherapy Center

[17] Yokohama City University Hospital,Center for Novel and Exploratory Clinical Trials

来源：

Annals of Surgical Oncology | 2019年 / 26卷

关键词：

Capecitabine Plus Oxaliplatin (CAPOX); Survival Outcomes; Gastric Cancer; pStage; Histological Type;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：465 / 472

页数：7

共 50 条

[1] Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
Nozomu Fuse
Hideaki Bando
Keisho Chin
Seiji Ito
Takaki Yoshikawa
Akira Tsuburaya
Masanori Terashima
Yoshiyuki Kawashima
Tetsu Fukunaga
Masahiro Gotoh
Yasunori Emi
Kazuhiro Yoshida
Eiji Oki
Seiji Takahashi
Hiroshi Kuriki
Kumi Sato
Mitsuru Sasako
Gastric Cancer, 2017, 20 : 332 - 340
[2] Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study
Fuse, Nozomu
Bando, Hideaki
Chin, Keisho
Ito, Seiji
Yoshikawa, Takaki
Tsuburaya, Akira
Terashima, Masanori
Kawashima, Yoshiyuki
Fukunaga, Tetsu
Gotoh, Masahiro
Emi, Yasunori
Yoshida, Kazuhiro
Oki, Eiji
Takahashi, Seiji
Kuriki, Hiroshi
Sato, Kumi
Sasako, Mitsuru
GASTRIC CANCER, 2017, 20 (02) : 332 - 340
[3] Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
Yu, Yuanyuan
Zhang, Zicheng
Meng, Qianhao
Ma, Yue
Fan, Xiaona
Sun, Jie
Wang, Guangyu
FRONTIERS IN ONCOLOGY, 2021, 11
[4] Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
Ren, Deng-Feng
Zheng, Fang-Chao
Zhao, Jun-Hui
Shen, Guo-Shuang
Ahmad, Raees
Zhang, Shui-Sheng
Zhang, Yu
Kan, Jie
Dong, Li
Wang, Zi-Yi
Zhao, Fu-Xing
Zhao, Jiu-Da
WORLD JOURNAL OF CLINICAL CASES, 2018, 6 (10) : 373 - 383
[5] Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study
Deng-Feng Ren
Fang-Chao Zheng
Jun-Hui Zhao
Guo-Shuang Shen
Raees Ahmad
Shui-Sheng Zhang
Yu Zhang
Jie Kan
Li Dong
Zi-Yi Wang
Fu-Xing Zhao
Jiu-Da Zhao
World Journal of Clinical Cases, 2018, (10) : 373 - 383
[6] A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer
Li, Ning
Wu, Hui
Xu, Xin
Wei, Qinming
Ding, Yongfeng
Liu, Shan
Wu, Jinqiong
Zheng, Yulong
Xu, Nong
Gao, Yuan
Jiang, Haiping
SCIENTIFIC REPORTS, 2024, 14 (01):
[7] Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study
Jiang, Zhichao
Sun, Yongkun
Zhang, Wen
Cui, Chengxu
Yang, Lin
Zhou, Aiping
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (03) : 180 - 186
[8] Adjuvant Chemotherapy With S-1 Plus Docetaxel Versus S-1 Plus Oxaliplatin in Stage III Gastric Cancer
Yamamoto, Masaaki
Omori, Takeshi
Shinno, Naoki
Hara, Hisashi
Mukai, Yosuke
Sugase, Takahito
Takeoka, Tomohira
Mikamori, Manabu
Kanemura, Takashi
Hasegawa, Shinichiro
Akita, Hirofumi
Haraguchi, Naotsugu
Nishimura, Junichi
Wada, Hiroshi
Matsuda, Chu
Yasui, Masayoshi
Miyata, Hiroshi
Ohue, Masayuki
ANTICANCER RESEARCH, 2023, 43 (11) : 5015 - 5024
[9] CYP2A6 Polymorphisms Associate with Outcomes of S-1 Plus Oxaliplatin Chemotherapy in Chinese Gastric Cancer Patients
Yang, Lin
Zou, Shanshan
Shu, Chang
Song, Yan
Sun, Yong-Kun
Zhang, Wen
Zhou, Aiping
Yuan, Xinghua
Yang, Yi
Hu, Songnian
GENOMICS PROTEOMICS & BIOINFORMATICS, 2017, 15 (04) : 255 - 262
[10] Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
Kazumasa Fujitani
Shigeyuki Tamura
Yutaka Kimura
Takeshi Tsuji
Jin Matsuyama
Shohei Iijima
Hiroshi Imamura
Kentaro Inoue
Kenji Kobayashi
Yukinori Kurokawa
Toshio Shimokawa
Toshimasa Tsujinaka
Hiroshi Furukawa
Gastric Cancer, 2014, 17 : 348 - 353

← 1 2 3 4 5 →